Angiotensin-Converting Enzyme-2 (ACE-2) with Interferon-Induced Transmembrane Protein-3 (IFITM-3) Genetic Variants and Interleukin-6 as Severity and Risk Predictors among COVID-19 Egyptian Population

Table 1

Comparison between the studied populations regarding sociodemographic data and associated comorbidities.

	Group I patients in wave 3 (n = 380)		Group II patients in wave 4 (n = 520)		Control (n = 100)
	No.	%	No.	%	No.	%
Gender
Male	238	62.6	301	57.9	59	59.0	0.352
Female	142	37.4	219	42.1	41	41.0
Age (years)
Min.–Max.	24.0–80.0		19.0–84.0		33.0–77.0		<0.001
Mean ± SD	62.85 ± 14.56		56.74 ± 14.94		58.26 ± 15.18
Sig. bet. grps.	, ,
Smoking	76	20.0	64	12.3	20	20.0	0.004
Obesity	20	5.3	40	7.7	5	5.0	0.280
Pregnancy	18	4.7	38	7.3	0	0.0	0.009
Comorbidities
DM	146	38.4	183	35.2	13	13.0	<0.001
Sig. bet. grps.	, ,
HTN	196	51.6	207	39.8	17	17.0	<0.001
Sig. bet. grps.	, ,
COPD	96	25.3	90	17.3	8	8.0	<0.001
Sig. bet. grps.	, ,
CHD	140	36.8	101	19.4	5	5.0	<0.001
Sig. bet. grps.	, ,
CKD	110	28.9	101	19.4	3	3.0	<0.001
Sig. bet. grps.	, ,
CLD	30	7.9	63	12.1	6	6.0	0.043
Sig. bet. grps.	, ,
Carcinoma	10	2.6	13	2.5	0	0.0	0.268
Vaccine	0	0.0	25	4.8	30	30.0	<0.001

Group I: patients of the third COVID-19 wave, group II: patients of the fourth COVID-19 wave, and SD: standard deviation. : value for comparing between the three studied groups. Sig. bet. grps: value for comparing between group I and group II and for comparing between both groups and control as follows: ₁: value for comparing between group I and group II. ₂: value for comparing between group I and controls. ₃: value for comparing between group II and controls. Statistically significant at . DM: diabetes mellitus, HTN: hypertension, COPD: chronic obstructive pulmonary disease, CHD: chronic heart disease, CKD: chronic kidney disease, and CLD: chronic liver disease.